Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
7 June 2021 |
Main ID: |
EUCTR2019-001653-99-FR |
Date of registration:
|
12/10/2020 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A placebo-controlled study of mirikizumab and vedolizumab in participants with
moderately to severely active ulcerative colitis
|
Scientific title:
|
A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active-
Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants with
Moderately to Severely Active Ulcerative Colitis - LUCENT-ACT |
Date of first enrolment:
|
26/11/2020 |
Target sample size:
|
1100 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001653-99 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
Croatia
|
Czech Republic
|
Denmark
|
France
|
Germany
|
Hungary
|
India
|
Italy
|
Japan
|
Korea, Republic of
|
Latvia
|
Lithuania
|
Malaysia
|
Mexico
|
Netherlands
|
Poland
|
Portugal
|
Romania
|
Russian Federation
|
Serbia
|
Slovakia
|
South Africa
|
Spain
|
Switzerland
|
Turkey
|
Ukraine
|
United Kingdom
|
United States
| | | | | | |
Contacts
|
Name:
|
Clinical Trial Registry Office
|
Address:
|
Lilly Corporate Center, DC 1526
IN 46285
Indianapolis
United States |
Telephone:
|
|
Email:
|
EU_Lilly_clinical_Trials@Lilly.com |
Affiliation:
|
Eli Lilly and Company |
|
Name:
|
Clinical Trial Registry Office
|
Address:
|
Lilly Corporate Center, DC 1526
IN 46285
Indianapolis
United States |
Telephone:
|
|
Email:
|
EU_Lilly_clinical_Trials@Lilly.com |
Affiliation:
|
Eli Lilly and Company |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: • Participants must have a diagnosis of UC for at least 3 months prior to baseline • Participants must have a confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS) • Participants must have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC • Participants must, if female, meet the contraception requirements
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1000 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 100
Exclusion criteria: • Participants must not have a current diagnosis of Crohn’s disease or inflammatory bowel disease-unclassified (indeterminate colitis) • Participants must not have had a previous colectomy • Participants must not have current evidence of toxic megacolon • Participants must not have prior exposure to anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab), vedolizumab, or natalizumab • Participants must not have prior clinical failure or intolerance to anti-IL12p40 antibodies (e.g. ustekinumab), anti-integrin antibodies other than vedolizumab and natalizumab (e.g. etrolizumab) or anti-integrin ligand antibodies (e.g. ontamalimab) within 4 weeks prior to screening endoscopy
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Moderately to Severely Active Ulcerative Colitis MedDRA version: 20.1
Level: LLT
Classification code 10045365
Term: Ulcerative colitis
System Organ Class: 100000004856
|
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
|
Intervention(s)
|
Product Name: mirikizumab Product Code: LY3074828 Pharmaceutical Form: Solution for infusion INN or Proposed INN: MIRIKIZUMAB CAS Number: 1884201-71-1 Current Sponsor code: LY3074828 Other descriptive name: MIRIKIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
Product Name: mirikizumab Product Code: LY3074828 Pharmaceutical Form: Solution for injection INN or Proposed INN: MIRIKIZUMAB CAS Number: 1884201-71-1 Current Sponsor code: LY3074828 Other descriptive name: MIRIKIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use
Trade Name: Entyvio Product Name: vedolizumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: vedolizumab CAS Number: 943609-66-3 Other descriptive name: VEDOLIZUMAB Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 300- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
|
Primary Outcome(s)
|
Primary end point(s): • Percentage of Participants in Histologic Remission based on histology.
|
Timepoint(s) of evaluation of this end point: Week 12
|
Secondary Objective: To evaluate the efficacy of mirikizumab on endoscopic improvement. To evaluate the efficacy of mirikizumab on histo-endo improvement.
|
Main Objective: To evaluate the efficacy of mirikizumab on histologic improvement
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Week 52 Week 12 for Percentage of Participants with Clinical Response Clinical response based on MMS.
|
Secondary end point(s): Percentage of Participants in Symptomatic Remission Symptomatic remission based on modified Mayo Score (MMS) stool frequency (SF) and rectal bleeding (RB) subscores.
Percentage of Participants in Clinical Remission Clinical remission based on MMS.
Percentage of Participants in Endoscopic Remission Endoscopic remission based on MMS ES.
Percentage of Participants with Clinical Response Clinical response based on MMS.
Percentage of Participants with Corticosteroid (CS) Free Remission without Surgery (Subgroup of Participants on CS at Baseline) CS free remission without surgery based on clinical remission, symptomatic remission and no CS use.
Percentage of Participants with Resolution of Extraintestinal Manifestations (EIMs) Among Those That had Them at Baseline Percentage of participants with resolution of EIMs among those that had them at baseline.
Change from Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score Change from baseline on the IBDQ score.
Percentage of Participants Undergoing Surgery for UC (Including Colectomy)
Percentage of Participants Hospitalized for UC
|
Secondary ID(s)
|
2019-001653-99-CZ
|
I6T-MC-AMBI
|
Source(s) of Monetary Support
|
Eli Lilly and Company
|
Ethics review
|
Status: Approved
Approval date: 26/11/2020
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|